Can a JAK inhibitor halt rapid lung decline?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Meet the diagnostic criteria for rapidly progressive interstitial lung disease (RP-ILD) and require treatment with corticosteroids and immunosuppressants, defined as: Acute worsening of cough and dyspnea occurring within 1 month; Chest CT showing ILD manifestations with new or worsening exudative lesions (ground-glass opacities and/or consolidation); Presence of respiratory failure (PaO₂ \< 60 mmHg at rest without oxygen supplementation, or SpO₂ \< 90% on room air), or significant worsening of hypoxemia (a decrease in PaO₂ of ≥ 10 mmHg), or a clear decline in two recent pulmonary function tests: a decrease in FVC % predicted of ≥ 10% and/or a decrease in DLCO % predicted of ≥ 15% accompanied by a decline in FVC; Exclusion of heart failure or fluid overload, pulmonary infectious diseases, and pulmonary embolism * No prior treatment with JAK inhibitors * Able to comply with scheduled follow-up visits * Patient and family members understand the study protocol, are willing to participate, and are able to provide written informed consent. Exclusion Criteria: * The patient or family members are unable to understand the conditions and objectives of this study, or are unable to provide informed consent * Subjects who are unable to comply with the follow-up schedule as required by the protocol, including those who cannot cooperate with pulmonary function testing * Presence of other severe diseases that, in the investigator's opinion, may affect patient safety or compliance * Any significant clinical or laboratory abnormalities that, in the investigator's opinion, may affect the safety evaluation * Oxygenation index ≤ 100, and/or requirement for invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) support * Pregnant or lactating women, as well as patients who are unable to use effective contraception during the study period and within 3 months after the end of the study * Presence of contraindications to golidocitinib administration, including a history of allergy to relevant drugs, or presence of active and uncontrolled infections, such as evidence of HIV, HBV (HBsAg-positive, HBV-DNA-positive or ≥ 1000 copies/mL), HCV (anti-HCV antibody-positive or HCV-RNA-positive), or any symptomatic bacterial, viral, parasitic, or fungal infection requiring treatment * Need for concomitant use of acetaminophen or propacetamol, or preparations containing these ingredients